4.8 Article

Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes

Journal

ONCOGENE
Volume 30, Issue 20, Pages 2333-2344

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.609

Keywords

neurofibromatosis type 2; arachnoid; brain tumours

Funding

  1. US Army Medical Research and Materiel Command [DAMD17-02-1-0645]
  2. James S McDonnell Foundation
  3. Association Neurofibromatoses et Recklinghausen
  4. Vincent Buono Research Fund
  5. Inserm

Ask authors/readers for more resources

Meningiomas are among the most common primary central nervous system tumours in adults. Studies focused on the molecular basis for meningioma development are hampered by a lack of information with regard to the cell of origin for these brain tumours. Herein, we identify a prostaglandin D synthase-positive meningeal precursor as the cell of origin for murine meningioma, and show that neurofibromatosis type 2 (Nf2) inactivation in prostaglandin D2 synthase (PGDS) (+) primordial meningeal cells, before the formation of the three meningeal layers, accounts for the heterogeneity of meningioma histological subtypes. Using a unique PGDSCre strain, we define a critical embryonic and early postnatal developmental window in which biallelic Nf2 inactivation in PGDS (+) progenitor cells results in meningioma formation. Moreover, we identify differentially expressed markers that characterize the two major histological meningioma subtypes both in human and mouse tumours. Collectively, these findings establish the cell of origin for these common brain tumours as well as a susceptible developmental period in which signature genetic mutations culminate in meningioma formation. Oncogene (2011) 30, 2333-2344; doi: 10.1038/onc.2010.609; published online 17 January 2011

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cell Biology

Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells

Luca Hegedues, Kata D. Szuecs, Matthias Kudla, Julian Heidenreich, Verena Jendrossek, Samuel Pena-Llopis, Tamas Garay, Andras Czirok, Clemens Aigner, Till Ploenes, Silvia Vega-Rubin-de-Celis, Balazs Hegedues

Summary: This study investigated the effect of Nintedanib on SRC kinase, one of its targets, in MPM cells. The results showed that Nintedanib did not inhibit SRC activation and even increased SRC phosphorylation in some MPM cell lines. However, combination treatment with the SRC inhibitor Dasatinib reversed this effect. The study also revealed that combination treatment promoted autophagy in MPM cells, which was independent of the AKT/mTOR and ERK pathways.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Article Oncology

The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer

Martin Metzenmacher, Balazs Hegedues, Jan Forster, Alexander Schramm, Peter A. Horn, Christoph A. Klein, Nicola Bielefeld, Till Ploenes, Clemens Aigner, Jens T. Siveke, Martin Schuler, Smiths S. Lueong

Summary: This study evaluated the clinical utility of cfRNA for early detection and surveillance of NSCLC. The results showed that MORF4L2 cfRNA was more abundant in patients and its combination with tumor markers improved the predictive value. Furthermore, low baseline MORF4L2 levels were associated with better patient survival and progression-free survival. cfRNA transcripts better reflected tumor dynamics compared to tumor markers. These findings suggest the potential clinical application of cfRNA for detection and monitoring of NSCLC.

THORACIC CANCER (2022)

Article Oncology

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow

Ildiko Kovacs, Edina Bugyik, Katalin Dezso, Julia Tarnoki-Zach, Elod Mehes, Marton Gulyas, Andras Czirok, Elisabeth Lang, Michael Grusch, Karin Schelch, Balazs Hegedus, Ildiko Horvath, Nandor Barany, Zsolt Megyesfalvi, Anna Tisza, Zoltan Lohinai, Mir Alireza Hoda, Konrad Hoetzenecker, Francesco Pezzella, Sandor Paku, Viktoria Laszlo, Balazs Dome

Summary: This study investigates the microanatomical steps of malignant pleural mesothelioma (MPM) vascularization and the resistance mechanisms to anti-angiogenic drugs in MPM. The study reveals two distinct growth patterns of orthotopically implanted human MPM xenografts, invasive pattern and pushing/desmoplastic pattern.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

Article Oncology

Preoperative PET-SUVmax and volume based PET parameters of the primary tumor fail to predict nodal upstaging in early-stage lung cancer

Ozlem Okumus, Khaled Mardanzai, Till Plones, Dirk Theegarten, Kaid Darwiche, Martin Schuler, Felix Nensa, Hubertus Hautzel, Ken Hermann, Martin Stuschke, Balazs Hegedus, Clemens Aigner

Summary: This study aimed to assess the association of preoperative PET parameters with nodal upstaging in lung adenocarcinoma and squamous cell carcinoma. The results showed that high preoperative PET-SUVmax values were associated with squamous cell carcinoma and larger tumors. However, SUVmax and metabolic PET parameters MTV and TLG were not significant predictors of nodal upstaging, except for tumor size and number of removed lymph nodes.

LUNG CANCER (2023)

Article Pharmacology & Pharmacy

Laser ablation-inductively coupled plasma-mass spectrometry analysis reveals differences in chemotherapeutic drug distribution in surgically resected pleural mesothelioma

Anna Tisza, Thomas Klikovits, Michal Benej, Szilvia Torok, Beata Szeitz, Zsuzsanna Valko, Mir Alireza Hoda, Balazs Hegedus, Maximilian Bonta, Winfried Nischkauer, Konrad Hoetzenecker, Andreas Limbeck, Karin Schelch, Viktoria Laszlo, Zsolt Megyesfalvi, Balazs Dome

Summary: This study examined platinum (Pt) levels in blood samples and surgically resected specimens from 25 pleural mesothelioma (PM) patients who had received neoadjuvant Pt-based chemotherapy. The results showed significant differences in Pt distribution between tumorous and non-tumorous areas of PM specimens. Serum Pt levels were found to correlate with tissue Pt levels, elapsed time from the last chemotherapy cycle, and overall survival.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy

Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger

Summary: Malignant pleural mesothelioma (MPM) is a deadly asbestos-related tumor with limited treatment options. This study examines the expression of two proteins, MSLN and CXCR4, in MPM tumor samples and their potential as targets for endo-radioligand therapy. The results show significant expression of these proteins in a majority of the samples, suggesting the possibility of using radioligand-based diagnostics and endo-radiotherapy for MPM patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy

Luca Hegedues, Oezlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedues

Summary: The expression of TROP2 and sensitivity to SN38 in MPM cell lines support the biomarker-selected clinical exploration of sacituzumab govitecan in patients with MPM.

LUNG CANCER (2023)

Article Multidisciplinary Sciences

Cellular mechanisms of heterogeneity in NF2-mutant schwannoma

Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A. Wright, Elizabeth A. Flynn, Shannon L. Stott, Marco Giovannini, Andrea I. McClatchey

Summary: Schwannomas are common tumors that develop on cranial and spinal nerves and are associated with neurofibromatosis type 2 (NF2). Despite genetic uniformity, schwannomas exhibit clinical and therapeutic heterogeneity. The mechanism behind this heterogeneity in NF2-mutant schwannomas is unknown.

NATURE COMMUNICATIONS (2023)

Article Oncology

Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis

Berta Mosleh, Karin Schelch, Thomas Mohr, Thomas Klikovits, Christina Wagner, Lukas Ratzinger, Yawen Dong, Katharina Sinn, Alexander Ries, Walter Berger, Bettina Grasl-Kraupp, Konrad Hoetzenecker, Viktoria Laszlo, Balazs Dome, Balazs Hegedus, Marko Jakopovic, Mir Alireza Hoda, Michael Grusch

Summary: This study found that FGF18 expression is elevated in pleural mesothelioma (PM) tissue compared to normal mesothelium. However, despite high mRNA levels in PM cells, circulating FGF18 protein is significantly lower in PM patients and patients with pleural fibrosis than in healthy controls. The results suggest that FGF18 is not a prognostic biomarker in PM, and further investigation is needed to understand its role in tumor biology and the clinical significance of decreased plasma FGF18 in PM patients.

THORACIC CANCER (2023)

Article Oncology

Early Detection of Lung Cancer Using Small RNAs

Tobias Sikosek, Rastislav Horos, Franziska Trudzinski, Julia Jehn, Maurice Frank, Timothy Rajakumar, Laura V. Klotz, Nathaniel Mercaldo, Mustafa Kahraman, Marco Heuvelman, Yasser Taha, Jennifer Gerwing, Jasmin Skottke, Alberto Daniel-Moreno, Marta Sanchez-Delgado, Sophie Bender, Christina Rudolf, Franziska Hinkfoth, Kaja Tikk, Judith Schenz, Markus A. Weigand, Peter Feindt, Christian Schumann, Petros Christopoulos, Hauke Winter, Michael Kreuter, Marc A. Schneider, Thomas Muley, Stephan Walterspacher, Martin Schuler, Kaid Darwiche, Christian Taube, Balazs Hegedus, Klaus F. Rabe, Kimberly Rieger-Christ, Francine L. Jacobsen, Clemens Aigner, Martin Reck, Alexander A. Bankier, Amita Sharma, Bruno R. Steinkraus

Summary: Lung cancer is the deadliest cancer and its survival is influenced by tumor stage. Low-dose computed tomography screening can reduce mortality but has low adherence in the US and limited implementation in Europe. Therefore, additional screening tests, such as blood tests, are needed for early detection in primary care settings.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Oncology

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation

Till Milde, Jason Fangusaro, Michael J. Fisher, Cynthia Hawkins, Fausto J. Rodriguez, Uri Tabori, Olaf Witt, Yuan Zhu, David H. Gutmann

Summary: Pediatric low-grade gliomas (pLGGs) are common brain tumors in young children, which often result in chronic tumor- and therapy-related morbidities. The growth of pLGGs is influenced by genetic alterations and nonneoplastic cells in the microenvironment. Preclinical models are necessary to identify potential drugs for clinical evaluation and improve treatment for children with pLGGs.

NEURO-ONCOLOGY (2023)

Editorial Material Medicine, Research & Experimental

Putting a stop to nonsense: Revisiting gene correction therapy for neurofibromatosis type 1

David H. Gutmann

MOLECULAR THERAPY-NUCLEIC ACIDS (2023)

Review Oncology

Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects

Yunshuo Tang, David H. Gutmann

Summary: Optic pathway glioma (OPG) occurs in a significant number of individuals with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome. While often benign and slow growing, some patients with NF1-OPGs experience symptoms such as vision loss and precocious puberty. Studies using genetically engineered Nf1-OPG mouse models have provided valuable insights into the molecular and cellular pathways of optic gliomagenesis and identified potential new treatments. Research focusing on determining the factors underlying optic glioma development and tumor-induced optic nerve injury will contribute to personalized risk assessment and improved treatment for children with NF1-OPG.

CANCER MANAGEMENT AND RESEARCH (2023)

Meeting Abstract Oncology

Early detection of lung cancer using small RNAs

Amita Sharma, Tobias Sikosek, Rastislav Horos, Timothy Rajakumar, Kaja Tikk, Christian Schumann, Stephan Walterspacher, Petros Christopoulos, Martin H. Schuler, Kaid Darwiche, Christian Taube, Balazs Hegedus, Klaus Rabe, Kimberly M. Rieger-Christ, Francine Jacobnson, Clemens Aigner, Alexander A. Bankier, Martin Reck, Bruno Steinkraus

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Children with supratentorial midline pilocytic astrocytomas exhibit multiple progressions and acquisition of neurologic deficits over time

Nicole M. Brossier, Jennifer M. Strahle, Samuel J. Cler, Michael Wallendorf, David H. Gutmann

NEURO-ONCOLOGY ADVANCES (2022)

No Data Available